Phase I study of weekly intravenous PS-341 [bortezomib] plus mitoxantrone in patients with advanced androgen-independent prostate cancer (Al-PCa).
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Bortezomib (Primary) ; Mitoxantrone (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Aug 2014 Planned primary completion date changed from 1 Mar 2015 to 1 Mar 2016, as per ClinicalTrials.gov record.